-
2 days ago | 
oncologynewscentral.com | Leah Lawrence
Combining two bispecific antibodies, talquetamab and teclistamab, led to a higher overall response rate (ORR) with deep, durable responses among patients with multiple myeloma and extramedullary disease (EMD), according to the results of the phase 2 RedirecTT-1 trial presented at the European Hematology Association 2025 Congress (Abstract LB4001).
-
3 days ago | 
ascopost.com | Leah Lawrence
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials comparing SLNB alone against SLNB with complete axillary lymph node dissection (ALND) and two trials comparing SLNB against no axillary surgery.2 “Several decades ago, we felt that we needed to know...
-
1 week ago | 
oncologynewscentral.com | Leah Lawrence
Post-transplant cyclophosphamide (PTCy) combined with cyclosporin significantly improved outcomes for patients with acute leukemia or myelodysplastic syndrome undergoing stem cell transplantation with a matched sibling donor, according to data from the BM12 CAST trial presented at the European Hematology Association 2025 Congress (Abstract S103) and published in the New England Journal of Medicine.
-
1 week ago | 
oncologynewscentral.com | Leah Lawrence
The combination of polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) significantly improved overall survival (OS) compared with rituximab, gemcitabine, and oxaliplatin (R-GemOx) alone in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to the results of the POLARGO trial presented at the European Hematology Association 2025 Congress (Abstract S101).
-
1 week ago | 
oncologynewscentral.com | Leah Lawrence
Treatment with ropeginterferon alfa-2b (ropeg; Besremi) showed superior efficacy to anagrelide as a second-line treatment for patients with high-risk essential thrombocythemia (ET) who were intolerant or resistant to hydroxyurea, according to results of the phase 3 SURPASS ET trial presented at the European Hematology Association 2025 Congress (S102).
-
2 weeks ago | 
oncologynewscentral.com | Leah Lawrence
Nearly 20 million people have watched a YouTube video of Joe Rogan’s podcast, The Joe Rogan Experience, featuring actor Mel Gibson. The most replayed portion of the more than two-hour-long podcast is a short segment where Gibson tells the host “a good story” of three friends who had stage IV cancer who do not have any cancer “right now at all.” According to Gibson, those three friends all took the antiparasitic drugs ivermectin and fenbendazole.
-
2 weeks ago | 
oncologynewscentral.com | Leah Lawrence
Until recently, advancements in the management of patients with small cell lung cancer (SCLC) had been limited. However, within the last five years, the U.S. Food and Drug Administration has approved several new immunotherapies and targeted therapies for patients with extensive-stage SCLC (ES-SCLC) and limited-stage SCLC (LS-SCLC). Oncology News Central recently spoke with Sandip P.
-
2 weeks ago | 
oncologynewscentral.com | Leah Lawrence
Brain metastasis is a common complication for patients with advanced melanoma. Treatment of these metastases can help with symptoms, slow tumor growth, and hopefully, extend or improve life. Oncology News Central recently spoke with Isabella C. Glitza Oliva, MD, PhD, professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, about recent advances in the management of central nervous system (CNS) disease in patients with melanoma.
-
2 weeks ago | 
oncologynewscentral.com | Leah Lawrence
The European Hematology Association (EHA) 2025 Congress kicks off on June 12 in Milan, Italy, and will provide updates “on the most recent breakthroughs in both clinical and translational hematology,” says Lorena Arranz, PhD, of the University of Oslo and Oslo University Hospital in Norway, and a member of the meeting’s Scientific Program Committee.
-
3 weeks ago | 
medcentral.com | Leah Lawrence
Opioid prescriptions for cancer pain significantly decreased during the five-year period from 2016 to 2021 among a sample of outpatients at a single tertiary cancer center, according to a recent study published in JCO Oncology Practice. Specifically, the number of patients who had not been prescribed any opioids increased from 28% in 2016 to 41% in 2021 (P=.008).
